Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferran Torres

Showing results (151-160 of 180) with videos related to

Pageof 18
Sort By:
The Journal of Antimicrobial Chemotherapy|March 22, 2008
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohortPere Domingo, Ignacio Suárez-Lozano, Ferran Torres, et al.
Journal of Nephrology|December 20, 2019
Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practiceDavid Cucchiari, José Ríos, Alicia Molina-Andujar, et al.
Journal of Hepatology|September 16, 2021
Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosisAdrià Juanola, Isabel Graupera, Chiara Elia, et al.
Journal of Hepatology|April 5, 2026
Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654]Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Journal of Hepatology|October 28, 2025
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 updateMaria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Hepatology (Baltimore, Md.)|February 28, 2019
Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective StudyPatricia Huelin, Elsa Solà, Chiara Elia, et al.
Journal of Hepatology|December 2, 2021
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodulesMarco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2026
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)Marco Sanduzzi-Zamparelli, Ana Matilla, José Luis Lledo, et al.
Journal of Hepatology|September 8, 2020
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope ConsortiumElsa Solà, Elisa Pose, Daniela Campion, et al.
Pageof 18

Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
The Journal of Antimicrobial Chemotherapy|March 22, 2008
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohortPere Domingo, Ignacio Suárez-Lozano, Ferran Torres, et al.
Journal of Nephrology|December 20, 2019
Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practiceDavid Cucchiari, José Ríos, Alicia Molina-Andujar, et al.
Journal of Hepatology|September 16, 2021
Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosisAdrià Juanola, Isabel Graupera, Chiara Elia, et al.
Journal of Hepatology|April 5, 2026
Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654]Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Journal of Hepatology|October 28, 2025
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 updateMaria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Hepatology (Baltimore, Md.)|February 28, 2019
Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective StudyPatricia Huelin, Elsa Solà, Chiara Elia, et al.
Journal of Hepatology|December 2, 2021
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodulesMarco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2026
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)Marco Sanduzzi-Zamparelli, Ana Matilla, José Luis Lledo, et al.
Journal of Hepatology|September 8, 2020
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope ConsortiumElsa Solà, Elisa Pose, Daniela Campion, et al.
Pageof 18